+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of brenipatide alongside standard of care SoC compared to a placebo plus SoC in adult participants with major depressive disorder. This Phase 3 trial aims to delay the return of major depressive symptoms and is sponsored by Eli Lilly and Company. Participants will be randomly assigned to receive one of three doses of brenipatide or a placebo, all administered by subcutaneous injection in addition to their standard treatment. The study includes a screening period lasting about one month, followed by a treatment period and potential post-treatment phase that together last at least 12 months. Throughout the trial, participants will self-inject the study medication and complete electronic and paper diaries along with questionnaires. Researchers will monitor the time to relapse of major depressive disorder and assess changes in depression rating scales, body weight, functional impairment, anxiety, quality of life, and other patient-reported outcomes. The follow-up period after treatment will last approximately 2 months.

Age: 18Years - 75YearsAll GendersPhase 3
180 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of NPX-5 in psilocybin-assisted psychotherapy PAP for treating adjustment disorder related to cancer diagnosis. This Phase IIb randomized, double-blind study compares three doses of NPX-5 25 mg, 10 mg, and 1 mg in adults aged 18 to 80 who experience anxiety after a stressful cancer diagnosis. The study aims to generate knowledge that could support new treatments for anxiety and depression following such events. Participants are randomly assigned to receive one of three NPX-5 doses during an approximately 8-hour PAP dosing session on Day 14. Those who do not respond by Week 10 may be offered a second PAP cycle at the 25 mg dose. A maximum of two PAP cycles can be administered. The study combines in-person clinic visits and telehealth sessions, including screening, preparation, dosing, integration, and follow-up visits, with remote and in-person therapy sessions involving a primary therapist and optionally a sitter or secondary therapist. Participants undergo screening and baseline assessments before treatment. They complete preparation sessions before dosing and attend follow-up visits at Weeks 4, 6, and 10, plus a final safety and tolerability assessment three months after the last PAP cycle. Researchers measure anxiety severity using the Hamilton Anxiety Rating Scale, monitor adverse events, and assess suicidality with the Sheehan Suicide Tracking Scale throughout the study. The total participation period includes up to two treatment cycles and long-term follow-up.

Age: 18Years - 80YearsAll GendersPhase 2
5 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of HB-1 compared to a placebo in adults aged 18 to 65 years diagnosed with Post-Traumatic Stress Disorder PTSD. This phase 2, multi-center, randomized, double-blind, placebo-controlled trial will include approximately 200 to 500 participants without severe neuropsychiatric or medical conditions. The study aims to better understand how HB-1 affects PTSD symptoms using established clinical assessments. Participants will receive HB-1, a dual active pharmaceutical ingredient tablet containing telmisartan and verapamil extended release, or a matching placebo. They will start with a lower dose of HB-1 taken once daily and may have their dose increased at Week 4 or Week 8 if symptoms have not sufficiently improved and no serious side effects have occurred. Treatment will continue for 12 weeks, followed by a safety follow-up one week after the last dose. Throughout the study, participants will attend visits at baseline, Week 4, Week 8, and Week 12 for symptom assessments using several clinical scales and questionnaires. Safety monitoring will include checking for adverse events, vital signs, ECGs, and lab tests. The primary outcome is the change in clinician-rated PTSD symptoms. The total participation time is about 13 weeks including treatment and follow-up.

Age: 18Years - 65YearsAll GendersPhase 2
16 locations